Linshan Zhu

Linshan Zhu

Auto-generated profile, based on publicly available information

Linshan Zhu

Alfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2018 in Current Opinion in Biomedical Engineering
Verified
Journal Article
Closed access
YPYijia Pan
Yijia Pan
SYSangpil Yoon
Sangpil Yoon
LZLinshan Zhu
Linshan Zhu
YWYingxiao Wang
Yingxiao Wang

12 June 2026 in Science Advances
Verified
Journal Article
Open access
TGTianze Guo
Tianze Guo
ZZZiyue Zhu
Ziyue Zhu
YQYunjia Qu
Yunjia Qu
XYXi Yu
Xi Yu
LZLinshan Zhu
Linshan Zhu
YWYingxiao Wang
Yingxiao Wang
CAR-T therapy is highly effective in hematologic malignancies but remains challenging in solid tumors. To address this challenge, here, we developed SHIFTERS (solid-tumor hallmark inducible, focused-ultrasound triggered enhanced reprogramming system), an AND-gated circuit that rewires tumor hallmarks into the clinically validated antigen CD19 under focused-ultrasound (FUS) control. SHIFTERS uses a split Gal4-VP64 transcription factor with one module driven by a hypoxia-responsive promoter and the other by a FUS-inducible heat-shock promoter, restricting CD19 induction to sonicated, hallmark-positive regions. This design enables robust, sustained local CD19 expression to activate and train CD19 synNotch CAR-T cells. In 3D spheroids and in vivo models, hypoxia-gated SHIFTERS combined with synNotch CAR-T cells achieved strong tumor suppression, supporting FUS-guided, localized activation. SHIFTERS is modular and can be adapted to tumor-type–specific promoters such as enAFP in hepatocellular carcinoma to enable both spatial and cell type–specific targeting. Together, SHIFTERS provides a modular, tumor-constrained, ultrasound-controllable platform to improve the precision and efficacy of CAR-T therapy for solid tumors.